Plasma miR-98-5p as a candidate biomarker of pain severity in oxaliplatin-induced peripheral neuropathy related to NGF and catecholamine dysregulation.

Authors

Yeongdon Ju, Go-Eun Choi, Aelee Jang

Published in

Frontiers in molecular biosciences. Volume 13. Pages 1884789. Epub Sep 08, 2026.

Abstract

Oxaliplatin-induced peripheral neuropathy (OIPN) is a common and severe adverse event in patients with gastrointestinal (GI) cancer who undergo oxaliplatin-based chemotherapy. Assessments remain largely dependent on a numeric rating scale (NRS), which is needed for early detection and objective quantification of pain intensity.
This study aimed to identify differentially expressed microRNAs (miRNAs) in plasma samples from 22 patients with GI cancer treated with oxaliplatin to elucidate the association between candidate miRNA expression levels, nerve growth factor (NGF), catecholamines, and NRS scores for peripheral neuropathic pain. High-throughput RNA sequencing was used to analyze miRNA expression profiles, and patients were stratified into Groups 1 (n = 10, no or mild pain) and 2 (n = 12, moderate or severe pain) based on their NRS scores. Correlations between variables were assessed using Spearman's rank-order correlation (r = 0.4031, P = 0.0629).
In Group 2, hsa-miR-98-5p was significantly upregulated and demonstrated the greatest potential to stratify patients by pain severity among the candidate miRNAs (The area under the curve = 0.8083, 95% CI: 0.6222-0.9944). Gene ontology enrichment analysis revealed that hsa-miR-98-5p was significantly associated with critical neuronal injury and repair signaling pathways. Patients in Group 2 exhibited decreased norepinephrine and dopamine levels, elevated NGF levels, and elevated cortisol levels, indicating potential alterations in the OIPN neuromodulatory systems.
These findings suggest that miR-98-5p is a candidate biomarker of pain severity in OIPN and may play a role in OIPN pathophysiology.

PMID:
42774042
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.